Josephine Mollon1, Joanne E Curran2,3, Samuel R Mathias4, Emma E M Knowles4, Phoebe Carlisle5, Peter T Fox6, Rene L Olvera6,7, Harald H H Göring2,3, Amanda Rodrigue4, Laura Almasy8, Ravi Duggirala2,3, John Blangero2,3, David C Glahn4,5. 1. Department of Psychiatry, Boston Children's Hospital, Harvard Medical School, 1 Autumn Street, BCH 3428, Boston, MA, 02115, USA. josephine.mollon@childrens.harvard.edu. 2. Department of Human Genetics, School of Medicine, University of Texas Rio Grande Valley, Brownsville, TX, USA. 3. South Texas Diabetes and Obesity Institute, School of Medicine, University of Texas Rio Grande Valley, Brownsville, TX, USA. 4. Department of Psychiatry, Boston Children's Hospital, Harvard Medical School, 1 Autumn Street, BCH 3428, Boston, MA, 02115, USA. 5. Olin Neuropsychiatry Research Center, Institute of Living, Hartford, CT, USA. 6. Research Imaging Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. 7. Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. 8. Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Abstract
AIMS/HYPOTHESIS: Type 2 diabetes is associated with cognitive impairments, but it is unclear whether common genetic factors influence both type 2 diabetes risk and cognition. METHODS: Using data from 1892 Mexican-American individuals from extended pedigrees, including 402 with type 2 diabetes, we examined possible pleiotropy between type 2 diabetes and cognitive functioning, as measured by a comprehensive neuropsychological test battery. RESULTS: Negative phenotypic correlations (ρp) were observed between type 2 diabetes and measures of attention (Continuous Performance Test [CPT d']: ρp = -0.143, p = 0.001), verbal memory (California Verbal Learning Test [CVLT] recall: ρp = -0.111, p = 0.004) and face memory (Penn Face Memory Test [PFMT]: ρp = -0.127, p = 0.002; PFMT Delayed: ρp = -0.148, p = 2 × 10-4), replicating findings of cognitive impairment in type 2 diabetes. Negative genetic correlations (ρg) were also observed between type 2 diabetes and measures of attention (CPT d': ρg = -0.401, p = 0.001), working memory (digit span backward test: ρg = -0.380, p = 0.005), and face memory (PFMT: ρg = -0.476, p = 2 × 10-4; PFMT Delayed: ρg = -0.376, p = 0.005), suggesting that the same genetic factors underlying risk for type 2 diabetes also influence poor cognitive performance in these domains. Performance in these domains was also associated with type 2 diabetes risk using an endophenotype ranking value approach. Specifically, on measures of attention (CPT d': β = -0.219, p = 0.005), working memory (digit span backward: β = -0.326, p = 0.035), and face memory (PFMT: β = -0.171, p = 0.023; PFMT Delayed: β = -0.215, p = 0.005), individuals with type 2 diabetes showed the lowest performance, while unaffected/unrelated individuals showed the highest performance, and those related to an individual with type 2 diabetes performed at an intermediate level. CONCLUSIONS/ INTERPRETATION: These findings suggest that cognitive impairment may be a useful endophenotype of type 2 diabetes and, therefore, help to elucidate the pathophysiological underpinnings of this chronic disease. DATA AVAILABILITY: The data analysed in this study is available in dbGaP: www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001215.v2.p2.
AIMS/HYPOTHESIS: Type 2 diabetes is associated with cognitive impairments, but it is unclear whether common genetic factors influence both type 2 diabetes risk and cognition. METHODS: Using data from 1892 Mexican-American individuals from extended pedigrees, including 402 with type 2 diabetes, we examined possible pleiotropy between type 2 diabetes and cognitive functioning, as measured by a comprehensive neuropsychological test battery. RESULTS: Negative phenotypic correlations (ρp) were observed between type 2 diabetes and measures of attention (Continuous Performance Test [CPT d']: ρp = -0.143, p = 0.001), verbal memory (California Verbal Learning Test [CVLT] recall: ρp = -0.111, p = 0.004) and face memory (Penn Face Memory Test [PFMT]: ρp = -0.127, p = 0.002; PFMT Delayed: ρp = -0.148, p = 2 × 10-4), replicating findings of cognitive impairment in type 2 diabetes. Negative genetic correlations (ρg) were also observed between type 2 diabetes and measures of attention (CPT d': ρg = -0.401, p = 0.001), working memory (digit span backward test: ρg = -0.380, p = 0.005), and face memory (PFMT: ρg = -0.476, p = 2 × 10-4; PFMT Delayed: ρg = -0.376, p = 0.005), suggesting that the same genetic factors underlying risk for type 2 diabetes also influence poor cognitive performance in these domains. Performance in these domains was also associated with type 2 diabetes risk using an endophenotype ranking value approach. Specifically, on measures of attention (CPT d': β = -0.219, p = 0.005), working memory (digit span backward: β = -0.326, p = 0.035), and face memory (PFMT: β = -0.171, p = 0.023; PFMT Delayed: β = -0.215, p = 0.005), individuals with type 2 diabetes showed the lowest performance, while unaffected/unrelated individuals showed the highest performance, and those related to an individual with type 2 diabetes performed at an intermediate level. CONCLUSIONS/ INTERPRETATION: These findings suggest that cognitive impairment may be a useful endophenotype of type 2 diabetes and, therefore, help to elucidate the pathophysiological underpinnings of this chronic disease. DATA AVAILABILITY: The data analysed in this study is available in dbGaP: www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001215.v2.p2.
Authors: Kathy F Yates; Victoria Sweat; Po Lai Yau; Michael M Turchiano; Antonio Convit Journal: Arterioscler Thromb Vasc Biol Date: 2012-09 Impact factor: 8.311
Authors: R L Olvera; C E Bearden; D I Velligan; L Almasy; M A Carless; J E Curran; D E Williamson; R Duggirala; J Blangero; D C Glahn Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2011-05-06 Impact factor: 3.568
Authors: Stefan L C Geijselaers; Simone J S Sep; Coen D A Stehouwer; Geert Jan Biessels Journal: Lancet Diabetes Endocrinol Date: 2014-08-24 Impact factor: 32.069
Authors: Geert Jan Biessels; Salka Staekenborg; Eric Brunner; Carol Brayne; Philip Scheltens Journal: Lancet Neurol Date: 2006-01 Impact factor: 44.182
Authors: Jerome A Yesavage; Lisa M Kinoshita; Art Noda; Laura C Lazzeroni; Jennifer Kaci Fairchild; Joy Taylor; Doina Kulick; Leah Friedman; Jauhtai Cheng; Jamie M Zeitzer; Ruth O'Hara Journal: Diabetes Metab Syndr Obes Date: 2014-05-08 Impact factor: 3.168
Authors: R E Marioni; J Yang; D Dykiert; R Mõttus; A Campbell; G Davies; C Hayward; D J Porteous; P M Visscher; I J Deary Journal: Mol Psychiatry Date: 2016-02-09 Impact factor: 15.992
Authors: Divya Yogi-Morren; Rachel Galioto; Sarah Elizabeth Strandjord; L Kennedy; Pooja Manroa; John P Kirwan; Sangeeta Kashyap; John Gunstad Journal: Cardiovasc Psychiatry Neurol Date: 2014-06-25
Authors: Anna N Senko; Rupert W Overall; Jan Silhavy; Petr Mlejnek; Hana Malínská; Martina Hüttl; Irena Marková; Klaus S Fabel; Lu Lu; Ales Stuchlik; Robert W Williams; Michal Pravenec; Gerd Kempermann Journal: PLoS Genet Date: 2022-04-04 Impact factor: 6.020